Baillie Gifford & Co
KYNB

Baillie Gifford & Co’s Kyntra Bio KYNB Stock Holding History

Baillie Gifford & Co’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22
Closed -$10.1K – 350
2023
Q1 		$10.1K Buy
22
+3
+16% +$1.59K ﹤0.01% 398
2022
Q4 		$7.48K Hold
19
– – ﹤0.01% 431
2022
Q3 		$6K Hold
19
– – ﹤0.01% 436
2022
Q2 		$5K Hold
19
– – ﹤0.01% 449
2022
Q1 		$6K Hold
19
– – ﹤0.01% 459
2021
Q4 		$7K Hold
19
– – ﹤0.01% 465
2021
Q3 		$5K Hold
19
– – ﹤0.01% 478
2021
Q2 		$12K Buy
19
+4
+27% +$2.3K ﹤0.01% 415
2021
Q1 		$13K Buy
15
+1
+7% +$1.06K ﹤0.01% 378
2020
Q4 		$13K Buy
+14
New +$14.7K ﹤0.01% 361

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baillie Gifford & Co's KYNB Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Kyntra Bio (KYNB) in Q2 2023, closing a stake of 22 shares — an estimated $10.1K sold.

Baillie Gifford & Co first reported a position in KYNB in Q4 2020 and held it in 10 quarters. The position peaked at $13K in Q1 2021. 152 funds tracked by Wall St. Rank hold KYNB as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Kyntra Bio position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 22 Kyntra Bio shares in Q2 2023, an estimated $10.1K.
  • Baillie Gifford & Co first reported a position in Kyntra Bio in Q4 2020 and held it in 10 quarters.
  • Baillie Gifford & Co's Kyntra Bio position peaked at $13K in Q1 2021.
  • 152 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.